Apoha has emerged from stealth with $36 million in funding to develop its Liquid State Intelligence platform, which aims to revolutionize the study of molecular behaviour. The company's technology provides large-scale empirical data on how matter behaves, with early commercial applications in pharmaceuticals, food, and materials.
Outpost Bio has raised $3.5 million in pre-seed funding to expand its AI-driven platform for modelling interactions in human microbiology. The company aims to support pharmaceutical and consumer sectors in drug design and health product development by combining automated experimentation with machine learning.
Vienna-based Flinn has secured $20 million in funding to enhance its AI-powered software for automating regulatory and quality management in medtech and pharmaceuticals. The company aims to expand its platform’s reach to cover more of the product development lifecycle and support international growth.
An obesity drug discovered using artificial intelligence has achieved over 31% weight loss in preclinical tests. The results underline AI's emerging role in pharmaceutical development and the fight against metabolic diseases. The research highlights the increasing impact of AI-driven approaches in healthcare innovation.
The Trump administration has delayed the release of TrumpRx, an online platform for purchasing discounted prescription drugs directly from pharmaceutical companies, as Democratic senators question the platform’s legality and oversight. Lawmakers have raised concerns regarding potential conflicts of interest and regulatory compliance. The delay coincides with scrutiny over how the government will monitor such direct-to-consumer pharmaceutical platforms.
Deloitte’s Mathias Cousin urges pharmaceutical leaders to rethink AI deployment. Instead of isolated pilots, he advocates for integrated, outcome-focused adoption and building organizational readiness to unlock value in a complex, regulated sector.
Bristol Myers Squibb (BMS), a global leader in biopharmaceuticals, is pioneering artificial intelligence (AI) solutions to transform the management of clinical trials and streamline internal talent development. By integrating advanced machine learning in patient-trial matching and launching a skills-based AI-powered talent marketplace, BMS is redefining operational efficiency and workforce agility.
The latest release of the Admiral R package brings an embedded AI-powered chatbot, experimental functions for pharmacokinetic analysis, and tools for anti-drug antibody datasets. The project demonstrates the growing role of artificial intelligence in pharmaceutical data science and open-source software.
Stay informed with curated insights delivered weekly to your inbox.